caa a22 4500 46578979X CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00171988 doi (NATIONALLICENCE)springer-10.1007/BF00171988 Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer [Elektronische Daten] [Theera Umsawasdi, Tyrone Felder, Diane Jeffries, Robert Newman] Summary: Fifteen patients with previously untreated extensive non-small cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (4-DMDR) at the dose of 10 mg/m2/day x 5 days every 3 weeks with routine administration of antiemetic drugs. They received a median of two courses of treatment with the cumulative dose range from 50-712.5 mg/m2. One patient achieved partial remission with a duration of 14 weeks. Two patients had minor responses with durations of 14 and 24 weeks. Stable disease occurred in three patients (21, 22, and 27 weeks). Median survival was 33 weeks (range 3-73 + weeks). Toxicities were tolerable. Neutropenia (< 1,000 mm3) occurred in only 16% of all treatment courses. Three patients developed correctable arrhythmias (two with atrial fibrillation and one with accelerated junctional rhythm). The cause of arrhythmia was unclear. No clinical evidence of congestive heart failure or decreased cardiac ejection fraction was observed. Nausea and vomiting were common but tolerable. Alopecia and mucositis were uncommon. Clinical pharmacokinetic studies were done in nine patients. However, plasma 4-DMDR levels were below the limit of detection (3 ng/ml). Because 4-DMDR has shown some activity in previously untreated E-NSCLC and the toxicities at this dose schedule are mild, we suggest that further studies of this drug at a higher dose in this schedule are indicated. Kluwer Academic Publishers, 1990 non-small cell lung cancer nationallicence chemotherapy of lung cancer nationallicence 4-demethoxydaunorubicin nationallicence idarubicin nationallicence 4-DMDR nationallicence treatment of advanced lung cancer nationallicence Umsawasdi Theera Sections of Head and Neck and Thoracic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, College of Pharmacy, Texas Southern University College of Pharmacy and Health Sciences, 77004, Houston, Texas, USA aut Felder Tyrone Section of Pharmacology, Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, College of Pharmacy, Texas Southern University College of Pharmacy and Health Sciences, 77004, Houston, Texas, USA aut Jeffries Diane Sections of Head and Neck and Thoracic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, College of Pharmacy, Texas Southern University College of Pharmacy and Health Sciences, 77004, Houston, Texas, USA aut Newman Robert Section of Pharmacology, Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, College of Pharmacy, Texas Southern University College of Pharmacy and Health Sciences, 77004, Houston, Texas, USA aut Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S73-S78 0167-6997 8<S73 1990 8 10637 https://doi.org/10.1007/BF00171988 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171988 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Umsawasdi Theera Sections of Head and Neck and Thoracic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, College of Pharmacy, Texas Southern University College of Pharmacy and Health Sciences, 77004, Houston, Texas, USA aut NATIONALLICENCE 700 1- Felder Tyrone Section of Pharmacology, Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, College of Pharmacy, Texas Southern University College of Pharmacy and Health Sciences, 77004, Houston, Texas, USA aut NATIONALLICENCE 700 1- Jeffries Diane Sections of Head and Neck and Thoracic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, College of Pharmacy, Texas Southern University College of Pharmacy and Health Sciences, 77004, Houston, Texas, USA aut NATIONALLICENCE 700 1- Newman Robert Section of Pharmacology, Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, College of Pharmacy, Texas Southern University College of Pharmacy and Health Sciences, 77004, Houston, Texas, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S73-S78 0167-6997 8<S73 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer